Metabolomics profile of 5649 users and nonusers of hormonal intrauterine devices in Finland
| Autor: | Elena Toffol, Oskari Heikinheimo, Pekka Jousilahti, Anna But, Anni Joensuu, Antti Latvala, Timo Partonen, Iris Erlund, Jari Haukka |
|---|---|
| Přispěvatelé: | Department of Public Health, University of Helsinki, Clinicum, Department of Obstetrics and Gynecology, HUS Gynecology and Obstetrics, Quantitative Genetics, Institute of Criminology and Legal Policy, Faculty Common Matters (Faculty of Education), HUS Psychiatry, Jari Haukka / Principal Investigator |
| Rok vydání: | 2022 |
| Předmět: |
discontinuation of use
Hormonal intrauterine devices Fatty Acids Intrauterine Devices Medicated Obstetrics and Gynecology Levonorgestrel Amino Acids Aromatic Cholesterol Cross-Sectional Studies fertile-aged 3123 Gynaecology and paediatrics Metabolic changes Metabolites Contraceptive Agents Female Humans duration of use Female Apolipoproteins A Finland Triglycerides Aged Intrauterine Devices |
| Zdroj: | American journal of obstetrics and gynecology. 227(4) |
| ISSN: | 1097-6868 |
| Popis: | Publisher Copyright: © 2022 The Author(s) Background: Use of hormonal intrauterine devices has grown during the last decades. Although hormonal intrauterine devices act mostly via local effects on the uterus, measurable concentrations of levonorgestrel are absorbed into the systemic circulation. The possible metabolic changes and large-scale biomarker profiles associated with hormonal intrauterine devices have not yet been studied in detail. Objective: To examine through the metabolomics approach the metabolic profile of patients using hormonal intrauterine devices and how this metabolic profile is affected by duration and discontinuation of use. Study Design: The study consisted of cross-sectional analyses of 5 population-based surveys (FINRISK and FinHealth studies), spanning from 1997 to 2017. All fertile-aged participants (18–49 years) in the surveys with available information on hormonal contraceptive use and metabolomics data (n=5649) were included in the study. Altogether, 211 metabolic measures of users of hormonal intrauterine devices (n=1006) were compared with those of nonusers of hormonal contraception (n=4643) via multivariable linear regression models. To allow comparison across multiple measures, association magnitudes were reported in standard deviation units of difference in biomarker concentration compared with the reference group. Results: After adjustment for covariates, levels of 141 metabolites differed in current users of hormonal intrauterine devices compared with nonusers of hormonal contraception (median difference in biomarker concentration, 0.09 standard deviation): lower levels of particle concentration of larger lipoprotein subclasses, triglycerides, cholesterol and derivatives, apolipoproteins A and B, fatty acids, glycoprotein acetyls, and aromatic amino acids. The metabolic pattern of hormonal intrauterine device use did not change according to duration of use. When comparing previous users and never-users of hormonal intrauterine devices, no significant metabolic differences were observed. Conclusion: The use of hormonal intrauterine devices was associated with several moderate metabolic changes previously associated with reduced arterial cardiometabolic risk. The metabolic effects were independent of duration of use of the hormonal intrauterine devices. Moreover, the metabolic profiles were similar after discontinuation of hormonal intrauterine device use and in never-users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect